Curanex Pharmaceuticals (CURX) Competitors

Curanex Pharmaceuticals logo
$4.66 -0.04 (-0.89%)
Closing price 03:59 PM Eastern
Extended Trading
$4.60 -0.06 (-1.25%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CURX vs. AARD, PYRGF, AGFY, RYM, and PLRZ

Should you buy Curanex Pharmaceuticals stock or one of its competitors? Curanex Pharmaceuticals's main competitors and comparable companies include Aardvark Therapeutics (AARD), PyroGenesis Canada (PYRGF), Agrify (AGFY), RYTHM (RYM), and Polyrizon (PLRZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Curanex Pharmaceuticals compare to Aardvark Therapeutics?

Curanex Pharmaceuticals (NASDAQ:CURX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$8.86N/A
Aardvark TherapeuticsN/AN/A-$57.59M-$3.34N/A

In the previous week, Aardvark Therapeutics had 5 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 7 mentions for Aardvark Therapeutics and 2 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.07 beat Aardvark Therapeutics' score of -0.11 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Curanex Pharmaceuticals Positive
Aardvark Therapeutics Neutral

Curanex Pharmaceuticals has a beta of -2.99, meaning that its share price is 399% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market.

Aardvark Therapeutics' return on equity of -89.27% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -146.24% -138.29%
Aardvark Therapeutics N/A -89.27%-80.39%

Aardvark Therapeutics has a consensus target price of $11.06, suggesting a potential upside of 861.96%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Curanex Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aardvark Therapeutics
2 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Aardvark Therapeutics beats Curanex Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to PyroGenesis Canada?

Curanex Pharmaceuticals (NASDAQ:CURX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Curanex Pharmaceuticals has a beta of -2.99, suggesting that its stock price is 399% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Curanex Pharmaceuticals has higher earnings, but lower revenue than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$8.86N/A
PyroGenesis Canada$9.14M3.06-$21.12M-$0.04N/A

In the previous week, Curanex Pharmaceuticals and Curanex Pharmaceuticals both had 2 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 1.07 beat PyroGenesis Canada's score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Curanex Pharmaceuticals Positive
PyroGenesis Canada Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Curanex Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -146.24% -138.29%
PyroGenesis Canada -115.14%N/A -60.81%

Summary

PyroGenesis Canada beats Curanex Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Agrify?

Agrify (NASDAQ:AGFY) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

6.0% of Agrify shares are held by institutional investors. 2.2% of Agrify shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Agrify. Agrify is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agrify$12.26M2.00-$41.75M-$22.65N/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$8.86N/A

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than Agrify. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 0 mentions for Agrify. Curanex Pharmaceuticals' average media sentiment score of 1.07 beat Agrify's score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Agrify Neutral
Curanex Pharmaceuticals Positive

Agrify has a beta of 9.96, meaning that its stock price is 896% more volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.99, meaning that its stock price is 399% less volatile than the broader market.

Curanex Pharmaceuticals has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Curanex Pharmaceuticals' return on equity of -146.24% beat Agrify's return on equity.

Company Net Margins Return on Equity Return on Assets
Agrify-424.11% -185.90% -72.67%
Curanex Pharmaceuticals N/A -146.24%-138.29%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agrify
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Curanex Pharmaceuticals beats Agrify on 8 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

RYTHM has a net margin of 9.84% compared to Curanex Pharmaceuticals' net margin of 0.00%. RYTHM's return on equity of 21.25% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
RYTHM9.84% 21.25% 5.51%
Curanex Pharmaceuticals N/A -146.24%-138.29%

RYTHM has a beta of 9.94, indicating that its stock price is 894% more volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.99, indicating that its stock price is 399% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Curanex Pharmaceuticals has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RYTHM$17.28M1.42-$33.26M-$5.27N/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$8.86N/A

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than RYTHM. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 0 mentions for RYTHM. RYTHM's average media sentiment score of 1.41 beat Curanex Pharmaceuticals' score of 1.07 indicating that RYTHM is being referred to more favorably in the media.

Company Overall Sentiment
RYTHM Positive
Curanex Pharmaceuticals Positive

Summary

RYTHM beats Curanex Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than Polyrizon. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.79 beat Curanex Pharmaceuticals' score of 1.07 indicating that Polyrizon is being referred to more favorably in the media.

Company Overall Sentiment
Polyrizon Very Positive
Curanex Pharmaceuticals Positive

Polyrizon's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PolyrizonN/A N/A N/A
Curanex Pharmaceuticals N/A -146.24%-138.29%

Polyrizon has a beta of -1.16, suggesting that its share price is 216% less volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.99, suggesting that its share price is 399% less volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyrizonN/AN/A-$3.34MN/AN/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$8.86N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Polyrizon beats Curanex Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CURX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CURX vs. The Competition

MetricCuranex PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.37M$13.38B$7.60B$11.72B
Dividend YieldN/A2.58%2.47%4.48%
P/E RatioN/A27.9733.5830.13
Price / SalesN/A6.798.275.60
Price / CashN/A15.6321.0121.90
Price / Book2.885.394.443.72
Net Income-$4.22M$2.88B$3.50B$393.88M
7 Day Performance-19.26%-5.24%-6.53%-6.07%
1 Month Performance0.82%-4.80%-4.93%-7.38%
1 Year Performance-53.43%-7.35%-1.73%-7.48%

Curanex Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CURX
Curanex Pharmaceuticals
0.5137 of 5 stars
$4.66
-0.9%
N/A-56.2%$7.37MN/AN/A6
AARD
Aardvark Therapeutics
3.1963 of 5 stars
$1.52
-4.4%
$11.56
+660.7%
-88.9%$33.26MN/AN/A28
PYRGF
PyroGenesis Canada
N/A$0.14
+2.4%
N/A-13.9%$32.26M$9.14MN/A88
AGFY
Agrify
N/A$16.05
-2.3%
N/A-38.8%$32.15M$12.26MN/A140
RYM
RYTHM
1.0032 of 5 stars
$14.32
-10.8%
N/A-41.3%$31.22M$70.82MN/A141

Related Companies and Tools


This page (NASDAQ:CURX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners